Business
Successful ASSERT Trial Results in Resverlogix Filing New RVX-208 Patent
Successful ASSERT Trial Results in Resverlogix Filing New RVX-208 Patent
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\n Nov. 29, 2010 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nPatent filing is based on synergistic findings suggesting enhanced\n plaque management with RVX-208 in combination with statins \n\n\nTSX Exchange Symbol: RVX\n\n\nCALGARY, Nov. 29 /CNW/ - Resverlogix Corp. ("Resverlogix" or the\n "Company") (TSX:RVX) is pleased to announce today that it has filed\n additional new patent protection based on novel findings derived from\n its recently completed ASSERT Phase 2 clinical trial. A new patent\n application has been filed for novel dosing combinations of RVX-208 and\n leading statin therapeutics. The patent was filed based on the results\n demonstrated in the ASSERT trial. Resverlogix' findings in a post-hoc\n analysis of ASSERT data revealed that RVX-208 in certain doses along\n with leading statin drugs markedly improved not only ApoA-I production,\n HDL and large HDL particles, but also important aspects of LDL and ApoB\n particles.  All of these positive changes took place in patients on the\n best standard of care currently available.\n\n\n"The bonus finding of ApoB and LDL lowering while on statins and not in\n placebo's was a surprise finding and is useful in selecting the best\n statin co-medications going forward for maximum treatment effect. The\n effects seem most efficacious in the leading stains, being Pfizer's\n Lipitor and AstraZeneca's Crestor. Resverlogix will further delineate\n this positive synergistic effect from a mecha...